DeepMed Research

VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1265744
Drug: GSK1265744 matching placebo
Drug: Moxifloxacin

First Posted Date: 2014-01-06

Last Posted Date: 2014-06-16

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 42

Registration Number: NCT02027454

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: DTG
Drug: CBZ

First Posted Date: 2013-10-23

Last Posted Date: 2014-01-27

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT01967771

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: Dolutegravir/abacavir/lamivudine FDC
Drug: Atazanavir
Drug: Ritonavir
Drug: Tenofovir/emtricitabine FDC

First Posted Date: 2013-07-29

Last Posted Date: 2024-02-20

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 499

Registration Number: NCT01910402

Locations: 🇬🇧
GSK Investigational Site, Tooting, London, United Kingdom

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

Phase 1

Completed

Conditions: HIV-associated Lipodystrophy Syndrome

Interventions: Drug: GSK1265744B (sodium salt) containing 14C-GSK1265744B
Drug: 150 mg GSK1265744B
Drug: Placebo

First Posted Date: 2013-05-07

Last Posted Date: 2013-11-03

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT01848340

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: Atazanavir
Drug: BMS-955176
Drug: Placebo matching with BMS-955176
Drug: Tenofovir
Drug: Ritonavir
Drug: Emtricitabine

First Posted Date: 2013-03-04

Last Posted Date: 2019-11-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 107

Registration Number: NCT01803074

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Conditions: Infection, Human Immunodeficiency Virus

First Posted Date: 2013-01-28

Last Posted Date: 2017-04-06

Lead Sponsor: ViiV Healthcare

Registration Number: NCT01776996

Locations: 🇨🇭
GSK Investigational Site, Zuerich, Switzerland

A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Dolutegravir 50 mg
Drug: Calcium Carbonate 1200 mg
Drug: Ferrous Fumarate 324 mg

First Posted Date: 2013-01-08

Last Posted Date: 2013-04-22

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 24

Registration Number: NCT01762995

A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions: Drug: GSK1265744 injectable suspension
Other: Placebo to match injectable suspension

First Posted Date: 2012-12-25

Last Posted Date: 2013-05-20

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 72

Registration Number: NCT01756131

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1265744 30 mg oral
Drug: Midazolam 3 mg oral + GSK1265744 30mg oral
Drug: GSK1265744 400 mg (200 nm)
Drug: GSK1265744 400 mg (1 micro m)
Drug: GSK1265744 400 mg (5 micro m)

First Posted Date: 2012-12-21

Last Posted Date: 2014-04-21

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 43

Registration Number: NCT01754116

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Relative Bioavailability Study of GSK1265744 Formulations

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Hepatitis

Interventions: Drug: GSK1265744 Na Salt Tablets
Drug: GSK1265744 Free Acid Nanomilled Capsules
Drug: GSK1265744 Free Acid Micronized Capsules

First Posted Date: 2012-07-24

Last Posted Date: 2016-08-12

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 18

Registration Number: NCT01648257

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy